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statistically significant SIR and AER for thyroid cancer and 
acute myeloid leukemia.  
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Purpose or Objective: Despite the use of RT before or after 
salvage haemopoeitic stem cell transplant for relapsed and 
refractory lymphoma, the indications, timing and benefit of 
radiotherapy are not well established and it is unlikely that 
these questions will be tested in a randomised study. We 
present the outcomes of a retrospective analysis of the 
benefit of radiotherapy given before or after HSCT for 
lymphoma.  
 
Material and Methods: We reviewed our transplant and 
radiotherapy databases to identify patients. Inclusion criteria 
were patients who underwent HSCT from 2004-2010 for 
refractory or relapsed lymphoma. Primary end point was 
progression-free survival (PFS) and secondary end point was 
overall survival (OS). Risk of relapse and death was compared 
for those who received radiotherapy and those who did not 
using Cox’ proportional hazards ratio using age at diagnosis as 
an independent predictor. Rates of death were analysed 
using Fisher’s exact test. 
 
Results: We identified 330 patients who underwent HSCT 
from 2004-2010 for relapsed lymphoma.72 patients had 
Hodgkins’s and 258 patients had non-Hodgkin’s lymphoma. 
The median age at diagnosis was 46.5 years (14.6-72 years). 
The median age at transplant was 50.6 years (17.4-73.2 
years). 121 patients (36%) underwent an allogeneic and 209 
patients (64%) underwent an autologous transplant. Median 
follow-up was 1.8 years (0.0-10.0 years).  
94 patients (28%) underwent radical RT before or after 
transplant (excluding TBI). 58 patients underwent 
radiotherapy before HSCT and 36 subsequent to HSCT. Of 
those who underwent RT before HSCT 64% were in remission 
going to HSCT compared with 75% of those who received RT 
after HSCT. There was a trend towards a shorter PFS for 
those who did not receive RT (HR1.72, 95% CI 0.96-3.67). 
There was no difference in mortality at 3 years between the 
two groups (p=0.78). There was no difference in OS between 
the two groups (HR=0.98, 95% 0.67-1.56). We are currently 
analysing the pattern of relapse and the impact of different 
variables on relapse and overall survival. 
 
Conclusion: Peri-transplant RT seems to offer a progression 
free survival benefit in patients with relapsed/refractory 
lymphoma undergoing HSCT although confirmation is 
required. 
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Purpose or Objective: Splenic irradiation has been used as 
first treatment for several hematological neoplasm, including 
chronic leukemia or myeloid malignancies, but with the 
availability of new drugs its application was restricted. In 
selected cases, not only with palliative intentions, irradiation 
can be useful treatment modality 
Material and Methods: Our study included 11 patients: 5 with 
chronic lymphocytic leukemia, 5 with high-grade B-cell 
lymphoma and 1 with diagnose of polycythaemia Vera. In 5 
patients the treatment was with radical intention (all of 
them with high grade lymphoma) and the rest were 
palliatives as treatment of pain or normalization of red blood 
cell that allows more time between transfusions. The doses 
were generally low with range between 5 and 10 Gy in 0.5Gy 
daily fractions because doses higher than 10Gy did not 
provide benefits according to literature.  
 
Results: We got 5 complete responses confirmed by PET but 
after 2 years 2 of them relapsed and were treated with 
radiotherapy again with the same scheme and obtain the 
same response to the present day. In terms of palliative 
intention, splenic irradiation provided a relief of pail from 6 
to 12 months, and in 4 patients the disease progressed 
without new splenic symptoms. One patient received 3 
courses of radiotherapy for painful splenomegaly with a gap 
of 12, 9 and 6 months without acute toxicity and died due to 
non-splenic leukemia progression.  
 
Conclusion: In selected patients who are not responsive, not 
suitable for systemic treatment or palliatives, splenic 
irradiation can be an efficient therapy with little toxicity and 
sustained response over time. f of pail from 6 to 12 months, 
and in 4 patients the disease progressed without new splenic 
symptoms. One patient received 3 courses of radiotherapy for 
painful splenomegaly with a gap of 12, 9 and 6 months 
without acute toxicity and died due to non-splenic leukemia 
progression.  
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Purpose or Objective: We evaluated the tumor response and 
clinical outcomes according to molecular subtypes in locally 
advanced breast cancer patient who received neo-adjuvant 
chemotherapy (NAC) followed by surgery and radiotherapy. 
 
Material and Methods: We retrospectively reviewed 400 
patients with clinical stage II-III breast cancer who received 
NAC followed by surgery and radiotherapy in Samsung Medical 
Center, between 2007 and 2011. Among these, 329 patients 
who completed recommended therapy were analyzed on 
clinical outcomes and prognostic factors, with focusing on 
the molecular subtypes. Luminal A and B, HER2-enriched, and 
triple-negative subgroups were identified according to the 
hormone receptor (ER and PR), HER2, and Ki-67 receptor 
status. 
 
Results: Overall pathologic complete response (pCR) rate 
after NAC were 20.1% and HER2- enriched subgroup was 
associated with the highest rates of pCR (43.6%), whereas 
luminal A showed the lowest rates of pCR (4.6%). A 
significant correlation was found between pathologic 
response (pCR vs. non-pCR) and molecular subtypes (p value 
<0.001). The median follow-up duration was 55 months 
(range, 5 to 98 months). The 5-year overall survival (OS) and 
disease-free survival (DFS) rates were 88.9% and 72.9%, 
respectively. In subgroup analysis, according to the 
pathologic response (pCR vs. non-pCR), triple-negative 
subtype proved significant difference in 5-year OS rate 
(100.0% vs. 71.6%, p value =0.005) and 5-year DFS rate (93.1% 
vs. 55.1%, p value <0.001). HER2-enriched subtype also 
showed significant difference in 5-year OS rate (100.0% vs. 
79.1%, p value =0.05). A distinct survival difference according 
to molecular subtypes was found especially in non-pCR group 
(5-year OS and DFS, p value <0.001, respectively), in 
contrast, pCR group did not show a statistical difference of 
survival according to molecular subtypes. When compared 
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with luminal A, only triple-negative breast cancer was 
significantly related with decreased 5-year OS and DFS rate 
(p value <0.001, respectively). 
 
Conclusion: Non-pCR group showed significantly decreased 5-
year OS and DFS rates than pCR group, especially in triple 
negative and HER2-enriched breast cancer patients. In the 
case of pCR, there was no difference in survival rates 
regardless of molecular subtypes. While a significant 
difference between survival rates and molecular subtypes 
was found in the patients who failed to attain pCR. Compared 
to luminal A, only triple-negative subtype was associated 
with distinctly decreased 5-year OS and DFS rates. 
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Purpose or Objective: Comparative outcome data after 
intraoperative radiotherapy (IORT) and external beam 
radiotherapy (EBRT) for breast cancer at >5ys median follow-
up are rare. We present a large, mature single-institution 
matched-pair-comparison reporting survival and relapse-rates 
in patients treated with either modality. 
 
Material and Methods: Complete datasets for 258 IORT-pts 
treated between 2000 and 2010 were matched with 258pts 
postoperatively treated with EBRT by age/histology/tumor 
size, grading/lymph-node-status/hormone-receptors/type of 
adjuvant therapy/surgical margins/treatment-date. EBRT was 
performed with 2 tangential fields to whole breast 
(50Gy/25fractions) and with 9-12MeV direct-electron-field-
boosts to tumor bed (10-16Gy/5-8 fractions). A non-
dedicated Linac (green-line-setup) with direct 8-12MeV 
electron fields (21Gy prescribed to 90%-isodose) delivered 
IORT. Relapse at surgical intervention site was classified as 
true local recurrence(LR). All recurrences in the treated 
breast (any quadrant) were classified as Ipsilateral 
Recurrence(IR). 
 
Results: Median follow-up was 79 months (12-156) for both 
groups. IR were 11 after IORT and 6 after EBRT. LR for IORT 
and EBRT groups were 8 and 3, respectively. Cumulative 
incidence of IR at 5ys were 2.3%(IORT) and 1.4%(EBRT), 
(p=n.s., HR 1.8 CI 95% 0.69-5). Cumulative incidence of LR at 
5ys was 1.5%(IORT) and 0.8%(EBRT), (p=n.s., HR 3.1 CI 95% 
0.8-11.3) Overall survival(OS) at 3/5ys was 
98.8%/96.1%(IORT) and 98.8%/95.3%(EBRT), (n.s.). Disease-
free survival(DFS) at 3/5 ys was 97.2%/93.2%(IORT) and 
98%/93.5%(EBRT) (n.s). Between IORT and EBRT, no 
differences in non-breast-cancer-related-deaths or second-
cancer-incidence were recorded. When analyzed according to 
ASTRO-criteria for accelerated-partial-breast-
irradiation(APBI), outcome was better in the APBI-suitable 
group than in the entire cohort and the APBI-unsuitable 
group. The IR at 5ys for APBI-suitable/cautionary/unsuitable 
were 0%/2,7%/8% respectively 
 
Conclusion: In line with published randomized-trial-data, IR-
rate was higher after IORT than after EBRT if no stringent 
patient selection was performed. Non-breast-cancer-
mortality and second-cancer-incidence did not differ 
between IORT and EBRT. In patients suitable for APBI 
according to ASTRO-criteria, similar IR-, LR- and OS-data 
indicate that IORT is a viable alternative to EBRT. 
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Purpose or Objective: The current standard treatment for 
early breast cancer is a combination of conserving surgery 
and endocrine therapy or that of endocrine therapy and 
chemotherapy or chemotherapy alone. Even after remarkable 
technical advances in breast cancer surgery, physical and 
mental invasion for patients after surgery is a problem to be 
solved. Also patients of dying from breast cancer for surgery 
denial exist. In this study, we evaluated the usefulness and 
safety of novel non-operative enzyme-targeting 
radiosensitization: Kochi Oxydol-Radiation Therapy for 
Unresectable Carcinoma, type II (KORTUC II) with endocrine 
therapy for stage I and II breast cancer.  
 
Material and Methods: From October 2006 to September 
2013, radiation therapy was performed for 44 women 
(median age 63years ranging from 37 to 88 years) of breast 
cancer (Stage 0; n=2, Stage I; n=19, and stage II; n=23). All 
patients refused both surgery and systemic chemotherapy. 
Radiation therapy performed was 44Gy/ 16fr/ 3.5W for total 
breast with field-in-field technique, then electron beam 
boost 9Gy / 3fr / 3days was added to the tumor bed. We 
injected the sensitizer (0.5% hydrogen peroxide solution + 
0.83% sodium hyaluronate) under ultrasound guidance, before 
radiation therapy twice a week. Median follow-up period was 
51 months (21-104 months). After the treatment, both PET-
CT and breast MR were performed every year.  
 
Results: About adverse event no skin symptoms more than 
grade3 was observed Beauty effect was excellent or good in 
all cases. Local recurrence was seen in only 2 case (4.5%). 
Distant metastasis was not observed. Only one patient died 
from other disease.  
 
Conclusion: From the results of this study it was suggested 
that KORTUC II followed by endocine therapy is effective and 
safe as the therapy for stage I and II breast cancer. 
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Purpose or Objective: Randomized trials have established 
the role of hypofractionated radiation therapy (HFRT) in 
early breast cancer. HFRT allows for less costly and more 
accessible treatment. However, there is paucity of data for 
HFRT in locally advanced breast cancer (LABC). We report 
the impact of HFRT in unselected breast cancer patients (all 
stages except metastatic, both BCS /MRM) and compared 
with CFRT for any differences in outcomes. 
 
Material and Methods: 463 patients of BCS/MRM treated 
between Jan’08 and July’13 with CFRT (50Gy/ 25fr) or 
HFRT(42.4Gy/16 fr or 40Gy/15) to the breast/chest wall (CW) 
± SCF ± Ax, treated in 2 time periods were retrospectively 
reviewed. RT was given by direct electron field/ bitangential 
photons to the CW and by latter to the breast. SCF ± Ax RT 
was given by enface photons (when indicated). All patients of 
BCS received a tumor bed boost. Statistical analysis to 
compare the 2 groups for survival outcomes, was done in 
Sept’15. The primary endpoint was to compare the 
differences in loco regional recurrences (LRR) between the 2 
groups. 
 
